View this email in your browser
Reseach Happy Hour
Home - Anesthesia - Research - Research Happy Hour - Email Announcement

Please join us for a virtual Research Happy Hour at the DACCPM!

Dear Colleagues,

We are delighted to have Dr. Jesse (Jay) D. Roberts Jr., M.D. M.S., speaking about his investigations of novel mechanisms of newborn lung injury, and how they informed his development of new therapies and a first-in-class molecular probe for detecting activation of the mechanisms in the injured newborn lung in vivo.

The meeting format will be 50% time for the presentation and 50% for discussion. Questions can be asked during the presentation and will be moderated. This format has been very successful, engaging, and inspiring for the participants. It allows us to explore details and gain insights beyond traditional talks. Some of you may know this format as the style of the legendary flow-volume-underworld meetings.

All talks and discussions are now featured at our new webpage: Research Happy Hour.

Tilo Winkler, host of this RHH

Upcoming

Add to Calendar >

Wednesday, February 28, 2024, 5:30 PM – 6:30 PM EST
Click to join: https://partners.zoom.us/j/86857640144

Photo of the speaker
Jesse D. Roberts Jr., M.D. M.S.
Associate Professor of Anaesthesia at Harvard Medical School, Pediatric Anesthesiologist and Associate Anesthetist at Massachusetts General Hospital (MGH), DACCPM, Principal Investigator, MGH Cardiovascular Research Center, Scientist in MGH Dept of Medicine, Division of Cardiology
 
Targeting transforming growth factor-beta (TGFb) to protect the development of the injured newborn lung
 
Many forms of injury to the newborn lung can cause abnormal extracellular matrix assembly, dysplastic alveolar formation, and derail normal vascular development. These processes lead to pulmonary airway and vascular disease, and to death or life-long disability. Although studies in relevant newborn animal models suggest that several mediators might play a role in the evolution of this disease, few exhibit the potential for specific therapeutic targeting and in vivo assessment. In this talk, I will present our work indicating that TGFb is activated in the injured mouse pup lung, how targeting it with neutralizing antibodies protects pulmonary development, and how our new insights into pathogenic TGFb mechanisms in the newborn lung allow us to develop a molecular probe that can detect its activity in vivo.